Literature DB >> 8141578

Improved medium for fluconazole susceptibility testing of Candida albicans.

J L Rodriguez-Tudela1, J V Martinez-Suarez.   

Abstract

We have compared fluconazole susceptibilities of 92 clinical isolates of Candida albicans by broth microdilution in two different media: standard RPMI 1640 (RPMI) and the same medium supplemented with 18 g of glucose per liter (RPMI-glucose). Preparation of media, drugs, and inocula, as well as incubation conditions, followed the preliminary recommendations of the National Committee for Clinical Laboratory Standards (Villanova, Pa.) antifungal agent working group for broth macrodilution tests with antifungal agents, adapted to microdilution. Microtiter plates were agitated for 5 min before spectrophotometric readings were performed with an automatic plate reader set at 405 mm. The MIC endpoint was defined as an inhibitory concentration calculated from the turbidimetric data as a function of the turbidity in the drug-free control wells. The mean absorbances in the drug-free wells in RPMI and RPMI-glucose were, respectively, 0.38 (41.6% transmission) and 0.99 (10.2% transmission) (P < 0.001; Student's t test). Despite the increased growth in RPMI-glucose, 98.9% of the C. albicans strains tested for fluconazole susceptibility yielded similar MICs (+/- 1 dilution) in both media. Moreover, strains with decreased susceptibility to fluconazole displaying similar MICs in both media are easier to detect in RPMI-glucose because of the greater differences between turbidimetric readings in wells with grown or fluconazole-inhibited cultures. This objective turbidimetric method, with an easy-to-read improved medium (RPMI with glucose), together with previous experience of the National Committee for Clinical Laboratory Standards antifungal agent subcommittee, could overcome some of the present problems associated with lack of reproducibility of azole susceptibility testing.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8141578      PMCID: PMC284394          DOI: 10.1128/AAC.38.1.45

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Azole drug resistance in Candida species.

Authors:  D W Warnock
Journal:  J Med Microbiol       Date:  1992-10       Impact factor: 2.472

2.  Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.

Authors:  A Espinel-Ingroff; C W Kish; T M Kerkering; R A Fromtling; K Bartizal; J N Galgiani; K Villareal; M A Pfaller; T Gerarden; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

3.  Standardized susceptibility testing of fluconazole: an international collaborative study.

Authors:  M A Pfaller; B Dupont; G S Kobayashi; J Müller; M G Rinaldi; A Espinel-Ingroff; S Shadomy; P F Troke; T J Walsh; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

4.  Effects of incubation temperature, inoculum size, and medium on agreement of macro- and microdilution broth susceptibility test results for yeasts.

Authors:  R A Cook; K A McIntyre; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

5.  Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo.

Authors:  T E Rogers; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

6.  Multicenter evaluation of four methods of yeast inoculum preparation.

Authors:  M A Pfaller; L Burmeister; M S Bartlett; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

7.  Collaborative investigation of variables in susceptibility testing of yeasts.

Authors:  M A Pfaller; M G Rinaldi; J N Galgiani; M S Bartlett; B A Body; A Espinel-Ingroff; R A Fromtling; G S Hall; C E Hughes; F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

8.  Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size.

Authors:  J N Galgiani; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

9.  Comparison study of broth macrodilution and microdilution antifungal susceptibility tests.

Authors:  A Espinel-Ingroff; T M Kerkering; P R Goldson; S Shadomy
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

10.  Microtiter broth dilution method for yeast susceptibility testing with validation by clinical outcome.

Authors:  M Radetsky; R C Wheeler; M H Roe; J K Todd
Journal:  J Clin Microbiol       Date:  1986-10       Impact factor: 5.948

View more
  39 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  In vitro susceptibilities of clinical yeast isolates to the new antifungal eberconazole compared with their susceptibilities to clotrimazole and ketoconazole.

Authors:  J M Torres-Rodríguez; R Mendez; O López-Jodra; Y Morera; M Espasa; T Jimenez; C Lagunas
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Influence of shaking on antifungal susceptibility testing of Cryptococcus neoformans: a comparison of the NCCLS standard M27A medium, buffered yeast nitrogen base, and RPMI-2% glucose.

Authors:  J L Rodríguez-Tudela; F Martín-Díez; M Cuenca-Estrella; L Rodero; Y Carpintero; B Gorgojo
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

4.  Genetic dissimilarity of two fluconazole-resistant Candida albicans strains causing meningitis and oral candidiasis in the same AIDS patient.

Authors:  J Berenguer; T M Diaz-Guerra; B Ruiz-Diez; J C Bernaldo de Quiros; J L Rodriguez-Tudela; J V Martinez-Suarez
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

5.  Influence of incubation time, inoculum size, and glucose concentrations on spectrophotometric endpoint determinations for amphotericin B, fluconazole, and itraconazole.

Authors:  M H Nguyen; C Y Yu
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

6.  Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis.

Authors:  J H Rex; P W Nelson; V L Paetznick; M Lozano-Chiu; A Espinel-Ingroff; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

7.  Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose.

Authors:  A Espinel-Ingroff; M Pfaller; M E Erwin; R N Jones
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

8.  Fluconazole and amphotericin B antifungal susceptibility testing by National Committee for Clinical Laboratory Standards broth macrodilution method compared with E-test and semiautomated broth microdilution test.

Authors:  J van Eldere; L Joosten; V Verhaeghe; I Surmont
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

9.  Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi.

Authors:  E Herreros; C M Martinez; M J Almela; M S Marriott; F G De Las Heras; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients.

Authors:  C Quereda; A M Polanco; C Giner; A Sánchez-Sousa; E Pereira; E Navas; J Fortún; A Guerrero; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.